Department of Orthopedic, The Second People's Hospital of Yibin, Yibin, China.
Department of Nephrology, The Second People's Hospital of Yibin, Yibin, China.
Medicine (Baltimore). 2024 May 31;103(22):e38463. doi: 10.1097/MD.0000000000038463.
Previous studies explored the prognostic value of pretreatment platelet count, fibrinogen, and d-dimer level in patients with several types of cancer, however, a comprehensive conclusion has not been reached in osteosarcoma patients.
PubMed, Web of Science, Embase, and CNKI databases were systematically searched for eligible studies up to May 09, 2023, and pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were calculated to assess the prognostic impact of these indicators in osteosarcoma patients.
Twelve studies from China consisting of 1682 patients were finally included. Our findings revealed that an elevated level of pretreatment platelet or d-dimer was associated with a worse outcome of overall survival (platelet: HR = 1.63, 95% CI: 1.18-2.26, P = .003; d-dimer: HR = 2.29, 95% CI: 1.58-3.31, P < .001).
Based on current evidence, pretreatment platelet count and d-dimer level could be good prognostic biomarkers for Chinese osteosarcoma patients. However, future validation is also needed.
先前的研究探讨了血小板计数、纤维蛋白原和 D-二聚体水平在多种类型癌症患者中的预后价值，但在骨肉瘤患者中尚未得出综合结论。
系统检索了 PubMed、Web of Science、Embase 和中国知网（CNKI）数据库，截至 2023 年 5 月 9 日，纳入符合条件的研究，并计算了合并的风险比（HRs）及其相应的 95%置信区间（CIs），以评估这些指标对骨肉瘤患者预后的影响。
最终纳入了来自中国的 12 项研究，共 1682 例患者。我们的研究结果表明，血小板或 D-二聚体的术前水平升高与总生存的不良结局相关（血小板：HR=1.63，95%CI：1.18-2.26，P=0.003；D-二聚体：HR=2.29，95%CI：1.58-3.31，P<0.001）。
基于目前的证据，血小板计数和 D-二聚体水平术前水平可以作为中国骨肉瘤患者的良好预后生物标志物，但还需要进一步验证。
